DK2301576T3 - Therapeutic use of anti-CS1 antibodies - Google Patents

Therapeutic use of anti-CS1 antibodies

Info

Publication number: DK2301576T3
Authority: DK; Denmark
Prior art keywords: antibodies; therapeutic use; therapeutic
Prior art date: 2004-03-29

Application number

DK10180748.5T

Other languages

Danish (da)

Inventor

Nicolas F Landolfi

Gao Liu

Marna Williams

Yun J Tso

Original Assignee

Abbott Biotherapeutics Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-03-29

Filing date

2004-11-08

Publication date

2012-12-10

2004-05-07 Priority claimed from US10/842,011 external-priority patent/US20050025763A1/en

2004-11-05 Priority claimed from US10/982,357 external-priority patent/US7709610B2/en

2004-11-08 Application filed by Abbott Biotherapeutics Corp filed Critical Abbott Biotherapeutics Corp

2012-12-10 Application granted granted Critical

2012-12-10 Publication of DK2301576T3 publication Critical patent/DK2301576T3/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

DK10180748.5T 2004-03-29 2004-11-08 Therapeutic use of anti-CS1 antibodies DK2301576T3 (en)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US55762204P	2004-03-29	2004-03-29
US55762004P	2004-03-29	2004-03-29
US55762104P	2004-03-29	2004-03-29
US10/842,011 US20050025763A1 (en)	2003-05-08	2004-05-07	Therapeutic use of anti-CS1 antibodies
US10/982,357 US7709610B2 (en)	2003-05-08	2004-11-05	Therapeutic use of anti-CS1 antibodies
EP04810631A EP1729803B1 (en)	2004-03-29	2004-11-08	Therapeutic use of anti-cs1 antibodies

Publications (1)

Publication Number	Publication Date
DK2301576T3 true DK2301576T3 (en)	2012-12-10

Family

ID=44597272

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK10180748.5T DK2301576T3 (en)	2004-03-29	2004-11-08	Therapeutic use of anti-CS1 antibodies

Country Status (9)

Country	Link
JP (1)	JP4758984B2 (en)
CY (1)	CY1115003T1 (en)
DK (1)	DK2301576T3 (en)
ES (1)	ES2393539T3 (en)
HK (2)	HK1099699A1 (en)
HR (1)	HRP20120975T1 (en)
IL (1)	IL243687A0 (en)
PT (1)	PT2301576E (en)
SI (1)	SI2301576T1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3384919A1 (en) *	2008-06-02	2018-10-10	Dana Farber Cancer Institute, Inc.	Cs1 peptides
EP3919069A1 (en)	2012-11-05	2021-12-08	Dana-Farber Cancer Institute, Inc.	Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
WO2015166056A1 (en) *	2014-05-02	2015-11-05	Cellectis	Cs1 specific multi-chain chimeric antigen receptor
TW202402806A (en) *	2018-05-18	2024-01-16	日商第一三共股份有限公司	Anti-muc1 antibody-drug conjugate
CN112442126B (en) *	2019-09-04	2022-07-29	杭州济元基因科技有限公司	Monoclonal antibody of anti-human CS1 antigen and CAR-T cell thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001046260A2 (en) *	1999-12-23	2001-06-28	Bristol-Myers Squibb Company	Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof

2004
- 2004-11-08 JP JP2007506135A patent/JP4758984B2/en not_active Expired - Lifetime
- 2004-11-08 DK DK10180748.5T patent/DK2301576T3/en active
- 2004-11-08 PT PT101807485T patent/PT2301576E/en unknown
- 2004-11-08 ES ES10180748T patent/ES2393539T3/en not_active Expired - Lifetime
- 2004-11-08 SI SI200431948T patent/SI2301576T1/en unknown
2007
- 2007-07-03 HK HK07107070.1A patent/HK1099699A1/en unknown
2011
- 2011-09-23 HK HK11110054.9A patent/HK1155670A1/en unknown
2012
- 2012-11-28 HR HRP20120975TT patent/HRP20120975T1/en unknown
- 2012-11-30 CY CY20121101174T patent/CY1115003T1/en unknown
2016
- 2016-01-19 IL IL243687A patent/IL243687A0/en unknown

Also Published As

Publication number	Publication date
HK1099699A1 (en)	2007-08-24
HRP20120975T1 (en)	2013-01-31
CY1115003T1 (en)	2016-12-14
PT2301576E (en)	2012-12-20
ES2393539T3 (en)	2012-12-26
JP4758984B2 (en)	2011-08-31
HK1155670A1 (en)	2012-05-25
IL243687A0 (en)	2016-04-21
SI2301576T1 (en)	2013-02-28
JP2007530675A (en)	2007-11-01

Publication	Publication Date	Title
CY2016035I2 (en)	2017-09-13	THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
LTPA2018515I1 (en)	2018-10-25	Antagonistic IL-17 Antibodies
DK1940465T3 (en)	2012-10-22	New use of anti-IL-1beta antibodies
DK1802579T3 (en)	2014-01-20	Derivatives of 3-arylaminopyridine
DK1778618T3 (en)	2014-03-10	Synthesis of triethylenetetramines
DK1720866T3 (en)	2011-11-21	Course of action
ATE501174T1 (en)	2011-03-15	ANTIBODIES AGAINST MADCAM
DK1587542T3 (en)	2012-07-30	Use of anti-CD100 antibodies
DK1802872T3 (en)	2009-08-17	Construction of gasline
ATE465180T1 (en)	2010-05-15	THERAPEUTIC ANTI-IGFR1 ANTIBODIES COMBINATIONS
NO20071430L (en)	2007-05-15	Anti-OX4OL antibodies
DK1992697T3 (en)	2010-05-17	Preparation of TNFR-Fc
DK1708992T3 (en)	2007-11-05	Sulfonamide derivatives for the treatment of diseases
DE602005012267D1 (en)	2009-02-26	N OF DEVICES
DK1639010T3 (en)	2020-09-07	THERAPEUTIC SURROGATE END POINT FOR ANTI-CTLA-4 BASED IMMUNTERAPY OF DISEASE
DK1763520T3 (en)	2009-02-09	Use of trisubstituted benzopyranones
DK1744781T3 (en)	2012-10-15	Treatment of infectious diseases
EP1789027A4 (en)	2009-09-23	Therapeutic use of anti-tf-antigen antibody
DK1812002T3 (en)	2012-02-06	Treatment of mastitis
NO20043305D0 (en)	2004-08-09	Preparation of lodixanol
HK1155670A1 (en)	2012-05-25	Therapeutic use of anti-cs1 antibodies
DK1730109T3 (en)	2008-09-29	Synthesis of pyrrole-2-carbonitriles
FR2877833B1 (en)	2007-10-12	CORRECTEUR OF LORDOSES
FI20041385A (en)	2006-04-28	Defining the axis of symmetry
FR2878601B1 (en)	2007-03-09	RING OF CROSSING OF CLOISON